Year: 2022

Update to NUDT15

NUDT15 update With the recent Crohn’s Disease update, we have also updated the way our software processes NUDT15 genetic data. Previously, the software assessed reported genotypes for NUDT15 rs116855232. With this update, we now assess drug-gene interactions with NUDT15 based on…

Read More

Update to Crohn’s Disease

All TreatGx users now have access to the updated Crohn’s disease treatment algorithm. Crohn’s Disease This comprehensive update incorporates information from AGA 2021[1] and ACG 2018[2] to help clinicians personalize treatment for their patients. A key update to this algorithm is…

Read More

Update to Chronic Obstructive Pulmonary Disease (COPD) – Acute Exacerbation

TreatGx users now have access to the updated treatment algorithm for Chronic Obstructive Pulmonary Disease (COPD) – Acute Exacerbation. As always, this update includes the TreatGx standard of providing personalized dosing based on kidney function, liver function, and drug interactions. This…

Read More

Update to Rheumatoid Arthritis

TreatGx users now have access to the updated treatment algorithm for Rheumatoid Arthritis. As always, this update includes the TreatGx standard of providing personalized dosing based on kidney function, liver function, and drug interactions. This is based on the 2021 American…

Read More

GenXys Named to the 2022 CB Insights Digital Health 150 List

GenXys recognized for achievements in precision prescribing platform   NEW YORK, December 7, 2022 — CB Insights today named GenXys to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022.   “From reimagining clinical care, to…

Read More

Post-Myocardial Infarction and Hyperlipidemia – Updates to statins

All TreatGx users now have access to the updated treatment algorithms for Post-Myocardial Infarction and Hyperlipidemia. As always, these updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions. In this update,…

Read More

GenXys Partners with Manchester University for Pharmacogenomics Education

Vancouver, Canada (November 2, 2022) – GenXys, the global leader in precision prescribing software with embedded pharmacogenetic (PGx) data, is teaming up with Manchester University (MU) for pharmacogenomics education. Together, GenXys and MU will help drive global awareness and education of…

Read More

Update to Atrial Fibrillation – Anticoagulation: Warfarin initiation

All TreatGx users now have access to the updated treatment algorithm for Atrial Fibrillation – Anticoagulation: Warfarin. Warfarin dosing update The atrial fibrillation anticoagulation algorithm now provides updated dosing information for warfarin, including recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)…

Read More

Updates to Bipolar 1 Disorder, Depression, and Heart Failure – Chronic

All TreatGx users now have access to the updated treatment algorithms for Depression, Bipolar 1 Disorder, and Heart Failure – Chronic. As always, all updates include the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, contraindications, allergies/intolerances, and drug-drug interactions. Depression…

Read More

GenXys Extends North American Market Coverage as Global Experts Confirm Need for Tools to Enable Pharmacogenetics

Vancouver, Canada (July 28, 2022) – GenXys, the award-winning global leader in precision prescribing software with embedded pharmacogenetic (PGx) capability, recently solidified deals with three North American laboratory companies – Inagene, SRx Health and Immunogenomics of Texas. Two of these labs…

Read More